智通财经APP获悉，和誉-B(02256)涨幅扩大逾12%，截至发稿，涨9.04%，报7.96港元，成交额5089.5万港元。
消息面上，和誉发布公告，其将在今年7月2日至5日在西班牙巴塞罗那举行的2025年欧洲肿瘤内科学会胃肠道肿瘤大会(“ESMOGI会议”)上汇报依帕戈替尼(Irpagratinib/ABSK-011)与阿替利珠单抗联用治疗晚期肝细胞癌(“HCC”)的最新2期临床试验数据。
平安证券指出，2024年和誉首次实现全年盈利，2025年公司启动不超过2亿港元新一轮的股票回购计划，进一步提升股东价值，同时再次彰显出管理团队对公司未来发展前景的坚定信心。该行指出，CSF-1R抑制剂匹米替尼预计2025年内中美递交治疗TGCT上市申请，同步推进匹米替尼治疗cGVHD及胰腺癌研发计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.